Financial News

Eli Lilly said its retatrutide cleared a late-stage trial in patients with obesity, with some of them shedding a third of their body weight over 80 weeks.

Eli Lilly (NYSE:LLY) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5% year over year, with Mounjaro at $8.66B (+125%) and Zepbound at $4.16B (+80%). CEO David Ricks told investors “2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue ... Can Eli Lilly Stock Reach $1800 by 2030? Here Is the Bull Case

Apogee Therapeutics, Inc. is rated a Hold, driven by promising data for the lead asset zumilokibart in atopic dermatitis. Read more on APGE stock here.

Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its own blank-check entity.

Lilly’s takeover of Engage Bio marks the seventh acquisition for the big pharma since the start of 2026.

Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes. At 80 weeks, all doses of retatrutide (4 mg, 9 mg, and 12 mg) met the p

The healthcare team covers Q1 results from pharma and medtech companies and provides a wrap-up of the key takeaways.

Eli Lilly (LLY) offers strong dividend growth with a 15.17% annual increase, a 22% payout ratio, and exceptional profitability. Despite modest yield, its financial health and explosive earnings growth make it a top dividend growth stock.

Participants who stayed on the drug lost around one-quarter of their body weight, potentially setting a new benchmark for rivals like Novo Nordisk.

CNBC's Annika Kim Constantino joins 'Squawk Box' with the latest news from Eli Lilly.

Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of

The 10 largest stocks now account for 41% of the S&P 500's market value, as investor money continues pouring.

The longevity industry is booming with high-tech tests, drugs, and medical devices. What to know for your health—and personal finances.

If you are looking for a GLP-1 investment, you can buy the leader, the underdog, or the upstart.

Novo Nordisk-linked pharmaceutical strength helped Denmark post a fourth straight quarter of economic expansion.

Eli Lilly (NYSE:LLY) has partnered with Collaborative Drug Discovery to make its AI drug discovery platform, Lilly TuneLab, more widely accessible. Biotech companies using CDD Vault can now access Lilly's predictive AI and machine learning tools directly in their existing research workflows. The agreement is designed to support broader data sharing and collaboration across drug discovery partners. Eli Lilly enters this partnership with strong recent stock performance and a high share price...

These stocks have declined this year, while the consensus estimates for the companies’ earnings per share have soared.

SAN CARLOS, Calif., May 20, 2026--Engage Biologics Inc. ("Engage"), a preclinical biotechnology company pioneering non-viral DNA delivery, today announced that it has been acquired by Eli Lilly and Company ("Lilly").

Collaborative Drug Discovery (CDD), the leading provider of data management solutions for the pharmaceutical and biotechnology industries, today announced an agreement with Eli Lilly and Company (Lilly) to integrate Lilly TuneLab, a collaborative AI/ML drug discovery platform, into CDD Vault.

Bristol Myers Squibb said on Wednesday it is partnering with Anthropic ‌to make its Claude AI model ‌available to over 30,000 employees in an effort to ​accelerate the discovery, development and delivery of new medicines. • Bristol said it will also leverage Claude Code, Anthropic's coding tool, and evaluate its ‌use in research, ⁠drug development, manufacturing and other commercial and medical affairs. • Agentic ​AI, which ​requires little human intervention, could increase clinical development productivity by about 35% to 45% ​over the ‌next five years, consultancy McKinsey said last ​year.

Eli Lilly claims in a civil lawsuit that it's the victim of a $200 million plus drug rebate fraud tied to Pentecostal church bishops and businesses.

(Bloomberg) -- The way Unilever Plc Chief Executive Officer Fernando Fernandez starts every meeting at the consumer products maker says a lot about the mindset of corporate bosses who fear their companies have lost their edge.Most Read from BloombergUS Lawmakers Plan New $130 Fee for Electric Vehicle OwnersHasbro Cancels Dungeons & Dragons Game From ‘Star Wars’ VeteranNATO Is Starting to Consider Hormuz Mission to Protect ShipsUS 30-Year Yield Hits Highest Since 2007 as Selloff DeepensMeta Begin

https://www.businesswire.com/news/home/20260520932076/en/Engage-Bio-Acquired-by-Lilly-to-Accelerate-Development-of-Non-Viral-Genetic-Medicines

Novo Nordisk's pipeline positions it closer to Eli Lilly than market sentiment suggests. Click here to see why NVO stock is a Buy.

On a recent episode of Earn Your Leisure titled “The #1 Investing Mistake Keeping You Broke,” co-host E delivered a blunt diagnosis for retail investors: stop trading the stocks you should be holding. “The ones that are leading now will lead,” he said, warning that top companies could compound 4,000% or 5,000% over five or ... “4,000% or 5,000% Over Five or Six Years”: Why Patient Investors in NVDA, AMD, and LLY Are Winning

The acquisition is Lilly’s latest push into genetic medicine, giving it a technology designed to overcome some of the field’s longstanding limitations.

The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened by the President of the United States and quietly outperforming nearly every healthcare benchmark anyway. Trump signed his “most favored nation” drug pricing executive order last May, tying what Medicare pays to lower prices in other ... Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.

Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.

Dell stock received two price-target hikes after the company detailed its strategy to capitalize on the AI megatrend.